Anaconda Biomed receives IDE approval for enrollment in ATHENA study

Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems, has announced that it has received conditional IDE approval from the U.S. Food and Drug Administration to begin the ATHENA study of its ANA Funnel Catheter.

The prospective, randomised, dual-arm, multi-center study will assess the safety and effectiveness of mechanical thrombectomy using the ANA5 Advanced Neurovascular Access (ANA Funnel Catheter) in combination with a stent retriever.

“The neurointerventional community is eager to assess this innovative technology, which is designed to enhance the efficiency of mechanical thrombectomy,” said Dr. Adnan Siddiqui, coordinating investigator of the ATHENA study. “Even a small difference in the revascularisation success after one pass can have a profound impact on the clinical outcomes of people with ischemic stroke.”

Studies have shown that flow arrest during mechanical thrombectomy can improve revascularisation rates and clinical outcomes at three months. However, the approach has been underutilised to date due to the limitations of current devices.

Sign up for Blog Updates